<DOC>
	<DOC>NCT00996489</DOC>
	<brief_summary>This is a post approval study of Coaptite® in the treatment of female urinary incontinence.</brief_summary>
	<brief_title>Post Approval Study of Coaptite® in the Treatment of Female Urinary Incontinence</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence, Stress</mesh_term>
	<criteria>Has female stress urinary incontinence that is due to intrinsic sphincter deficiency Has a baseline pad weight of greater than or equal to 50 grams Has viable mucosal lining at likely site of injection (bladder neck) Is at least 18 years of age Understands and accepts the obligation and is logistically able to present for all scheduled study visits Signs written informed consent Has had a previous treatment for urinary incontinence with a urethral bulking agent other than Coaptite® or collagen Has detrusor instability Has bladder neuropathy Has nocturnal enuresis (bed wetting) Has Grade II or III prolapsed bladder Has overflow or functional incontinence Has significant history of urinary tract infections without resolution Has current or acute conditions of cystitis or urethritis Has history of significant pelvic irradiation Is pregnant or lactating</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>